SK285383B6 - Kompozície matrice s modifikovaným uvoľňovaním, sdlhodobým účinkom - Google Patents

Kompozície matrice s modifikovaným uvoľňovaním, sdlhodobým účinkom Download PDF

Info

Publication number
SK285383B6
SK285383B6 SK5022-2004A SK50222004A SK285383B6 SK 285383 B6 SK285383 B6 SK 285383B6 SK 50222004 A SK50222004 A SK 50222004A SK 285383 B6 SK285383 B6 SK 285383B6
Authority
SK
Slovakia
Prior art keywords
weight
pharmaceutically acceptable
zidovudine
lamivudine
composition
Prior art date
Application number
SK5022-2004A
Other languages
English (en)
Slovak (sk)
Other versions
SK50222004A3 (sk
Inventor
Himadri Sen
Surya Kumar Jayanthi
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Limited filed Critical Lupin Limited
Publication of SK50222004A3 publication Critical patent/SK50222004A3/sk
Publication of SK285383B6 publication Critical patent/SK285383B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
SK5022-2004A 2002-04-23 2002-04-23 Kompozície matrice s modifikovaným uvoľňovaním, sdlhodobým účinkom SK285383B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2002/000110 WO2003090762A1 (en) 2002-04-23 2002-04-23 Long acting compositions comprising zidovudine and lamivudine

Publications (2)

Publication Number Publication Date
SK50222004A3 SK50222004A3 (sk) 2005-05-05
SK285383B6 true SK285383B6 (sk) 2006-12-07

Family

ID=29266770

Family Applications (1)

Application Number Title Priority Date Filing Date
SK5022-2004A SK285383B6 (sk) 2002-04-23 2002-04-23 Kompozície matrice s modifikovaným uvoľňovaním, sdlhodobým účinkom

Country Status (12)

Country Link
US (1) US20050175694A1 (de)
EP (1) EP1501521B1 (de)
AT (1) ATE361080T1 (de)
AU (1) AU2002311622A1 (de)
BR (1) BR0215707A (de)
CZ (1) CZ20041117A3 (de)
DE (1) DE60219965T2 (de)
ES (1) ES2286258T3 (de)
HU (1) HUP0500217A2 (de)
MX (1) MXPA04010436A (de)
SK (1) SK285383B6 (de)
WO (1) WO2003090762A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0620705A2 (pt) * 2005-12-14 2011-11-22 Cipla Ltd formulação farmacêutica em uma forma única de dosagem unitária, produto farmacêutico, uso de uma formulação farmacêutico e uso de um inibidor de transcriptase-reversa de nucleosìdeo ou derivado fisiologicamente funcional do mesmo e um inibidor de transcriptase-reversa de nucleotìdeo ou derivado fisiologicamente funcional do mesmo
CA2721586A1 (en) * 2008-04-15 2009-10-22 Mallinckrodt Inc. Compositions containing antiviral compounds and methods of using the same
CN102488671A (zh) * 2011-12-15 2012-06-13 合肥华方医药科技有限公司 一种拉米夫定控释片制剂及其制备方法
CN113660928B (zh) * 2019-04-05 2024-04-05 盖迪亚生物技术公司 阴道片剂制剂
CN115813970B (zh) * 2022-11-25 2024-05-07 深圳福山生物科技有限公司 一种稳定释放的营养靶向组合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
DE69327004T2 (de) * 1992-08-04 2000-06-29 James M Dunn Pharmazeutische formulierungen mit kontrollierter freigabe von 3'-azido-3'-deoxythymidin und verfahren zur verwendung
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
EE200100153A (et) * 1998-09-14 2002-06-17 Ranbaxy Laboratories Limited Kontrollitav ravimiväljutussüsteem ravimite suukaudseks manustamiseks, mis pakub ajalist ja ruumilist kontrolli

Also Published As

Publication number Publication date
DE60219965D1 (de) 2007-06-14
US20050175694A1 (en) 2005-08-11
WO2003090762A1 (en) 2003-11-06
ES2286258T3 (es) 2007-12-01
AU2002311622A1 (en) 2003-11-10
HUP0500217A2 (hu) 2005-06-28
BR0215707A (pt) 2005-05-03
SK50222004A3 (sk) 2005-05-05
MXPA04010436A (es) 2005-05-27
EP1501521A1 (de) 2005-02-02
ATE361080T1 (de) 2007-05-15
DE60219965T2 (de) 2008-01-17
CZ20041117A3 (cs) 2005-04-13
EP1501521B1 (de) 2007-05-02

Similar Documents

Publication Publication Date Title
US20090208579A1 (en) Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060193911A1 (en) Controlled release venlafaxine formulations
NO319434B1 (no) Farmasoytisk oral doseform av ranolazin-preparater med depotvirkning og en komprimert tablett.
KR20020075801A (ko) 울혈성 심부전 치료의 부분적 지방산 산화 방지제
JP2009137996A (ja) ミコフェノール酸またはミコフェノール酸塩を含む医薬組成物
JP2008069159A (ja) 持続放出ラノラジン製剤
JPH11505542A (ja) 毎日一回投与するための、非晶質活性成分の一定のかつ制御された放出を行う三相型医薬製剤
ZA200402369B (en) Dosage form for treatment of diabetes mellitus
JP2008069159A5 (de)
EP1820506B1 (de) Dipyridamol enthaltende Zusammensetzungen mit verlängerter Freisetzung und Verfahren zu deren Herstellung
EP3131533A1 (de) Orale darreichungsform von ketamin
AU2001240092A1 (en) Sustained release ranolazine formulations
JP2011516613A (ja) 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
KR20180083239A (ko) 리마프로스트 또는 리마프로스트 알파엑스를 함유한 경구용 서방성 제제 조성물
JP2010536798A (ja) 難溶性薬物の生体利用率を制御するための方法及び組成物
CA2835272A1 (en) Pharmaceutical antiretroviral composition
US20070292505A1 (en) Controlled release alfuzosin hydrochloride formulation
SK285383B6 (sk) Kompozície matrice s modifikovaným uvoľňovaním, sdlhodobým účinkom
US20100285119A1 (en) Multiparticulate Extended Release Pharmaceutical Composition Of Carbamazepine And Process For Manufacturing The Same
KR20190120093A (ko) 레날리도마이드의 경구용 코팅 정제 조성물
WO2019132839A1 (en) Oral pharmaceutical compositions of dabigatran
EP1490034A1 (de) Pharmazeutische zusammensetzungen enthaltend eine antihistaminische abschwellende arzneistoffkombination und ein verfahren zur herstellung davon
WO2007143290A2 (en) Delayed-release compositions of extended release forms of venlafaxine
ZA200408203B (en) Long acting compositions comprising zidovudine and lamivudine

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20090423